| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA5208299
Max Phase: Preclinical
Molecular Formula: C26H23N5O4
Molecular Weight: 469.50
Associated Items:
Representations
Canonical SMILES: COc1cc(C(=O)NC2CC2)ccc1Nc1nc(Oc2cccc3c2C(=O)CC3)c2cc[nH]c2n1
Standard InChI: InChI=1S/C26H23N5O4/c1-34-21-13-15(24(33)28-16-7-8-16)5-9-18(21)29-26-30-23-17(11-12-27-23)25(31-26)35-20-4-2-3-14-6-10-19(32)22(14)20/h2-5,9,11-13,16H,6-8,10H2,1H3,(H,28,33)(H2,27,29,30,31)
Standard InChI Key: YQGSMIQRGJAWNI-UHFFFAOYSA-N
Associated Targets(Human)
Focal adhesion kinase 1 4730 Activities
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 469.50 | Molecular Weight (Monoisotopic): 469.1750 | AlogP: 4.52 | #Rotatable Bonds: 7 |
| Polar Surface Area: 118.23 | Molecular Species: NEUTRAL | HBA: 7 | HBD: 3 |
| #RO5 Violations: 0 | HBA (Lipinski): 9 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: 11.80 | CX Basic pKa: 3.70 | CX LogP: 3.97 | CX LogD: 3.97 |
| Aromatic Rings: 4 | Heavy Atoms: 35 | QED Weighted: 0.36 | Np Likeness Score: -0.77 |
References
| 1. Wei W, Feng Z, Liu Z, Li X, He H, Ran K, Shi Y, Zhu Y, Ye T, Gao C, Wang N, Yu L.. (2022) Design, synthesis and biological evaluation of 7-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-2,3-dihydro-1H-inden-1-one derivatives as potent FAK inhibitors for the treatment of ovarian cancer., 228 [PMID:34810020] [10.1016/j.ejmech.2021.113978] |
Source
Source(1):